Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vaginal vault

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    118 result(s) found for: Vaginal vault. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2004-005138-38 Sponsor Protocol Number: 2602-415 Start Date*: 2005-02-07
    Sponsor Name:Hvidovre Hospital
    Full Title: Antibiotikaprofylakse ved vaginalplastik
    Medical condition: Uterine prolapse grade I-II, cystocele and/or rectocele and/or enterocele grade I - IV and/or defects of the perineal body where there is medical indication for vaginal repair, but no indication fo...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-021621-12 Sponsor Protocol Number: NAI114373 Start Date*: 2010-12-01
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: NAI114373: A Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of ...
    Medical condition: hospitalised adults and adolescents with influenza
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) FR (Completed) GB (Completed) HU (Completed) NL (Completed) CZ (Completed) NO (Completed) DK (Completed) GR (Completed) BE (Completed) PL (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-003242-22 Sponsor Protocol Number: BCX4161-303 Start Date*: 2015-12-17
    Sponsor Name:BioCryst Pharmaceuticals Inc
    Full Title: OPuS-4: An open-label study to evaluate the long-term safety of avoralstat in subjects with hereditary angioedema
    Medical condition: Hereditary Angioedema
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10019860 Hereditary angioedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) BE (Completed) FR (Prematurely Ended) GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003075-35 Sponsor Protocol Number: CTT116855 Start Date*: 2014-07-24
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination fluticasone furoate/ umeclidinium/vi...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) PL (Completed) SE (Completed) DE (Completed) AT (Completed) CZ (Completed) BE (Completed) DK (Completed) ES (Completed) NO (Completed) RO (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2010-022383-12 Sponsor Protocol Number: CCX114157 Start Date*: 2011-02-16
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 52 week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects with Crohn’s Disease
    Medical condition: Subjects with Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Completed) NO (Prematurely Ended) BE (Completed) SE (Prematurely Ended) GB (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) GR (Prematurely Ended) AT (Completed) ES (Prematurely Ended) PL (Prematurely Ended) PT (Prematurely Ended) EE (Prematurely Ended) IT (Completed) SK (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003627-38 Sponsor Protocol Number: H3M116477 Start Date*: 2013-01-30
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) CZ (Completed) BG (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000879-14 Sponsor Protocol Number: CT/11.01 Start Date*: 2011-06-06
    Sponsor Name:Hellenic Oncology Research Group (H.O.R.G.)
    Full Title: A Phase II Trial of Pazopanib, in Relapsed and Refractory Small Cell Lung Cancer (SCLC).
    Medical condition: Relapsed and Refractory Small Cell Lung Cancer
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001804-39 Sponsor Protocol Number: GLLC-EARLY Start Date*: 2019-09-24
    Sponsor Name:Fundación PETHEMA
    Full Title: Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression
    Medical condition: Early Stage CLL With High Risk of Early Disease Progression
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002501-22 Sponsor Protocol Number: PHP-303-A201 Start Date*: 2020-05-04
    Sponsor Name:pH Pharma Inc.
    Full Title: A Multi-Center, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Tolerability of the Neutrophil Elastase Inhibitor PHP-303 in Adults with Alpha-1 Antitrypsin Defic...
    Medical condition: Alpha-1 Antitrypsin Deficiency
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-001575-23 Sponsor Protocol Number: 201884 Start Date*: 2017-09-21
    Sponsor Name:GlaxoSmithKline KK
    Full Title: Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese Subjects.
    Medical condition: Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000018399 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-004851-19 Sponsor Protocol Number: AAPSMCS1002 Start Date*: 2014-07-29
    Sponsor Name:ACORN Research, LLC
    Full Title: A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma.
    Medical condition: Surgically unresectable or metastatic chondrosarcoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002744-27 Sponsor Protocol Number: CR01849 Start Date*: 2011-11-01
    Sponsor Name:Imperial College
    Full Title: Pharmacodynamic Studies of a Histone Deacetylase Inhibitor in FRDA
    Medical condition: Friedreich’s ataxia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10017374 Friedreich's ataxia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2007-006287-29 Sponsor Protocol Number: AC2110664 Start Date*: 2008-06-20
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Dose ranging study for GSK233705B delivered once daily in subjects with COPD.
    Medical condition: Chronic Obstructive Pulmonary (COPD) disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) NL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-003073-10 Sponsor Protocol Number: CTT116853 Start Date*: 2014-09-16
    Sponsor Name:GlaxoSmithKline Research and Development
    Full Title: A Phase III, 24 week, randomized, double blind, double dummy, parallel group study (with an extension to 52 weeks in a subset of subjects) comparing the efficacy, safety and tolerability of the fix...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) SK (Completed) GR (Completed) DE (Completed) CZ (Completed) PL (Completed) BG (Completed) EE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2019-003405-94 Sponsor Protocol Number: ABY-035-202 Start Date*: 2020-05-05
    Sponsor Name:ACELYRIN, Inc.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, dose-finding clinical trial inpatients with active psoriatic arthritis to investigate efficacy, tolerability, safety, pharmacokinetics a...
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) CZ (Completed) DE (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001737-27 Sponsor Protocol Number: 54767414AMY3001 Start Date*: 2018-04-16
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnos...
    Medical condition: AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis )
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10002022 Amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) GR (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002333-19 Sponsor Protocol Number: OMS112831 Start Date*: 2011-11-29
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Randomized, Double-blind, Placebo controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months’ administration of Ofatumumab in Subjects with Relapsing-...
    Medical condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10070716 Multiple sclerosis pseudo relapse LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) NL (Completed) DK (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022382-10 Sponsor Protocol Number: CCX114151 Start Date*: 2011-01-06
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to Severely Active Crohn’s Disease
    Medical condition: Subjects with Moderately-to-Severely Active Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) CZ (Completed) SE (Prematurely Ended) NO (Completed) BE (Completed) DK (Completed) HU (Completed) IT (Completed) SK (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-019157-17 Sponsor Protocol Number: OTX113390 Start Date*: 2010-10-18
    Sponsor Name:GlaxoSmithKline Research and Development LTD
    Full Title: Evaluation of the safety and tolerability of re-dosing with intravenous (IV)otelixizumab in adult subjects with newly diagnosed type 1 diabetes mellitus.
    Medical condition: Autoimmune new onset type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067584 Type 1 diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-023348-33 Sponsor Protocol Number: DB2113361 Start Date*: 2011-04-05
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a N...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed) BE (Completed) SK (Completed) EE (Completed) SE (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 12:35:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA